Home > Result Summaries: Compounds > abacavir/lamivudine/zidovudine > Result Summary for AZL40001

Result Summary for AZL40001

Result Summary

Protocol ID:	AZL40001
Clinical Study ID:	AZL40001
Official Title:	An open-label, single arm, multicentre, pilot phase IV study to evaluate the efficacy and safety of a potent combination therapy (Trizivir + Efavirenz) in antiretroviral nave adults with a CD4+ cell count <200mm3 over a 48-week treatment period (TETRA Trizivir Efavirenz TReAtment)
Phase:	Phase 4
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus
Generic Name:	abacavir/lamivudine/zidovudine
Trade/Product Name:	trizivir;trizivir
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Easterbrook P, Wilkins E, Gazzard B, et al., Efficacy and Tolerability of Trizivir plus Efavirenz in Antiretroviral Nave Adults with Advanced HIV Disease at 48 Weeks: The TETRA Study. Poster 4745, ICAAC 2003, Poster P4745 Wilkins E, Gazzard B, Easterbrook P et al., Efficacy of Quad Therapy in Antiretroviral Naïve Adults with Very Low CD4 Cell Counts: The TETRA Study. 6th International Congress on Drug Therapy in HIV Infection, 2002, Poster P13